Please try another search
For the fiscal year ended 31 March 2022, Wakamoto Pharmaceutical Co Ltd revenues decreased 6% to Y8.38B. Net income applicable to common stockholders totaled Y238.5M vs. loss of Y601.9M. Revenues reflect Net Sales Of Finished Goods decrease of 5% to Y7.72B, Net sales of goods decrease of 13% to Y499.2M. Net Income reflects SP Loss Retirement of Fixed Assets decrease of 97% to Y390K (expense), NOP Other Expenses decrease of 72% to Y150K (expense).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 2116.74 | 2259.32 | 2041.67 | 1965.41 |
Gross Profit | 1126.16 | 1183.35 | 994.54 | 1051.85 |
Operating Income | 80.33 | 76.4 | -128.03 | -47.54 |
Net Income | 28.29 | 98.42 | 67.17 | 44.66 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 14953.43 | 14690.55 | 14717.66 | 14505.34 |
Total Liabilities | 3472.63 | 3330.47 | 3397.4 | 3212.25 |
Total Equity | 11480.8 | 11360.08 | 11320.26 | 11293.09 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 12 Months | 0 Months | 6 Months | 0 Months |
Cash From Operating Activities | 339.17 | 168.89 | ||
Cash From Investing Activities | 50.57 | 285.92 | ||
Cash From Financing Activities | -1.62 | -1.06 | ||
Net Change in Cash | 388.13 | 453.75 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review